NCIC CLINICAL TRIALS GROUP

LUNG

DISEASE SITE COMMITTEE MEETING
AGENDA

Delta Chelsea Hotel, Toronto, Ontario
Saturday, April 28, 2007 - 8:30 am – 4:15 pm EST
Room: CHURCHILL A

Chair: Frances Shepherd

8:30 a.m. WELCOME AND ANNOUNCEMENTS
Dr. F. Shepherd

8:35 a.m. SUB-COMMITTEE REPORTS

Small Cell
Dr. P. Ellis
Radiation
Dr. Y. Ung
Mesothelioma and Thymoma
Dr. C. Lee
Correlative Sciences
Dr. M-S Tsao

9:15 a.m. NON-SMALL CELL LUNG CANCER

SURGICAL ADJUVANT AND NEOADJUVANT AND LOCALLY ADVANCED TRIALS

BR.16 - Randomized placebo controlled trial of adjuvant selenium in completely resected stage I NSCLC (ECOG)
Dr. M. Johnston

BR.19 - Randomized trial of adjuvant gefitinib versus placebo after complete resection of Stage IB, II IIIA NSCLC
Dr. G. Goss

BR.23 - Phase II trial of etoposide/cisplatin/XRT followed by surgery and consolidation docetaxel for Pancoast tumours (SWOG 0220)
Dr. G. Perry

BRC.2 - ECOG 1505 Randomized trial of chemotherapy +/- bevacizumab in completely resected Stage IB-IIIA NSCLC
Dr. C. Butts

BRC.2 - ECOG 1505 Randomized trial of chemotherapy +/- bevacizumab in completely resected Stage IB-IIIA NSCLC
Dr. N. Leighl

Economic analysis

CALGB 140503 A Phase III randomized trial of lobectomy versus sub-lobar resection for small (≤2cm) peripheral NSCLC
Dr. G. Darling

10:30 a.m. COFFEE BREAK (~15 MIN)

continued . . .
10:45 a.m.  **ADVANCED NSCLC**

BR.24 - Randomized trial of paclitaxel and carboplatin +/- AZD 2171 in advanced Non-SCLC  Dr. S. Laurie

N0723 - A Phase III biomarker validation study of second-line therapy in patients with advanced NSCLC randomized to pemetrexed versus erlotinib  Dr. G. Liu

Proposal for erlotinib +/- talactoferrin in 2nd & 3rd Line treatment of NSCLC  Dr. F. Shepherd

11:30 a.m.  **SMALL CELL LUNG CANCER**

BR.20 - Randomized Phase II trial of ZD 6474 versus placebo in responding patients with SCLC. Final Report  Dr. A. Arnold

Proposals and decision re radiation trial for LD SCLC  Dr. A. Bezjak

Chemotherapy +/- low molecular weight heparin  Dr. C. Butts

Etoposide/platinum +/- pomalidomide in extensive SCLC  Dr. F. Shepherd

12:00 p.m.  **LUNCH (90 Min.)**

1:30 p.m.  **IND STUDIES**

IND.171 - Phase I/II trial of paclitaxel/carboplatin + AZD 2171  Dr. S. Laurie

IND.175 - Phase I/II trial of gemcitabine/cisplatin + AZD 2171  Dr. G. Goss

IND.180 - A Phase I/II trial of oral AMG706 with concurrent Etoposide/cisplatin/XRt in Stage III NSCLC  Dr. M. Florescu

IND.183 - Phase II trial of sutent in 2nd-line treatment of malignant mesothelioma  Dr. S. Laurie

Report from the IND Committee  Dr. G. Goss

2:30 p.m.  **RADIOTHERAPY STUDIES**

BR.25 - Hypofractionated radiotherapy for medically inoperable NSCLC  Dr. P. Cheung

BRC.1 - PCI in Non-SCLC  Dr. A. Sun

RTOG - PCI in SCLC  Dr. A. Sun

3:00 p.m.  **COFFEE BREAK (~15 Min.)**

3:15 p.m.  **ECONOMIC AND DATA-BASE ANALYSES OF LUNG TRIALS**

Economic analyses - active and planned  Dr. N. Leighl

Database analyses  Dr. F. Shepherd